Manning & Napier Advisors LLC purchased a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 101,848 shares of the company's stock, valued at approximately $1,979,000.
A number of other institutional investors have also bought and sold shares of CLBT. New York State Common Retirement Fund boosted its position in Cellebrite DI by 2.6% during the fourth quarter. New York State Common Retirement Fund now owns 189,599 shares of the company's stock valued at $4,177,000 after acquiring an additional 4,838 shares during the last quarter. Handelsbanken Fonder AB bought a new stake in Cellebrite DI during the fourth quarter valued at $3,937,000. Y Intercept Hong Kong Ltd boosted its position in Cellebrite DI by 37.4% during the fourth quarter. Y Intercept Hong Kong Ltd now owns 26,811 shares of the company's stock valued at $591,000 after acquiring an additional 7,301 shares during the last quarter. True Wind Capital Management L.P. boosted its position in shares of Cellebrite DI by 18.2% during the 4th quarter. True Wind Capital Management L.P. now owns 13,861,007 shares of the company's stock worth $305,358,000 after purchasing an additional 2,130,386 shares in the last quarter. Finally, Tower View Wealth Management LLC boosted its position in shares of Cellebrite DI by 1.3% during the 4th quarter. Tower View Wealth Management LLC now owns 132,307 shares of the company's stock worth $2,915,000 after purchasing an additional 1,660 shares in the last quarter. Institutional investors own 45.88% of the company's stock.
Cellebrite DI Trading Up 0.9%
Shares of CLBT traded up $0.14 on Tuesday, reaching $16.26. The company's stock had a trading volume of 1,519,290 shares, compared to its average volume of 1,474,978. Cellebrite DI Ltd. has a twelve month low of $11.47 and a twelve month high of $26.30. The stock has a market capitalization of $3.89 billion, a PE ratio of -16.94, a PEG ratio of 3.25 and a beta of 1.32. The firm has a fifty day moving average of $17.72 and a 200-day moving average of $19.72.
Cellebrite DI (NASDAQ:CLBT - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported $0.10 earnings per share for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The company had revenue of $107.55 million for the quarter, compared to analyst estimates of $109.36 million. During the same quarter in the prior year, the business posted $0.08 EPS. The firm's revenue was up 20.0% compared to the same quarter last year. As a group, equities analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities analysts have recently issued reports on the stock. JPMorgan Chase & Co. cut their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a research report on Monday, May 12th. Needham & Company LLC reissued a "buy" rating and set a $24.00 price objective on shares of Cellebrite DI in a research report on Friday, June 6th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Cellebrite DI currently has a consensus rating of "Buy" and an average target price of $22.43.
View Our Latest Report on CLBT
Cellebrite DI Company Profile
(
Free Report)
Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.
Further Reading
Before you consider Cellebrite DI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cellebrite DI wasn't on the list.
While Cellebrite DI currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.
Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
